MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Syndax Pharmaceuticals Inc

Open

SectorHealthcare

12.44 -1.66

Overview

Share price change

24h

Current

Min

12.13

Max

12.97

Key metrics

By Trading Economics

Income

-10M

-94M

Sales

-4.8M

7.7M

EPS

-1.1

Profit margin

-1,226.159

Employees

270

EBITDA

-5.3M

-89M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+179.65% upside

Dividends

By Dow Jones

Next Earnings

7 May 2025

Market Stats

By TradingEconomics

Market Cap

-188M

1.1B

Previous open

14.1

Previous close

12.44

News Sentiment

By Acuity

11%

89%

10 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Syndax Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

29 Jul 2024, 12:35 UTC

Major Market Movers

Syndax Pharma Shares Fall Premarket After FDA Extends Revumenib Review

Peer Comparison

Price change

Syndax Pharmaceuticals Inc Forecast

Price Target

By TipRanks

179.65% upside

12 Months Forecast

Average 36.27 USD  179.65%

High 51 USD

Low 16 USD

Based on 13 Wall Street analysts offering 12 month price targets forSyndax Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

12

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

11.625 / 13.12Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

10 / 386 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.